Yasmine Wasfi - Oct 17, 2025 Form 3 Insider Report for Savara Inc (SVRA)

Role
Chief Medical Officer
Signature
/s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi
Stock symbol
SVRA
Transactions as of
Oct 17, 2025
Transactions value $
$0
Form type
3
Date filed
10/22/2025, 08:44 PM
Next filing
Oct 22, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wasfi Yasmine Chief Medical Officer ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE /s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi 2025-10-22 0002092127

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SVRA Common Stock 155K Oct 17, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SVRA Stock Option (Right to Buy) Oct 17, 2025 Common Stock 110K $4.13 Direct F2
holding SVRA Stock Option (Right to Buy) Oct 17, 2025 Common Stock 175K $3.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 80,000 represents RSUs that vest in full on December 4, 2025; and 75,000 represents RSUs that vest in full on December 12, 2026, in each case subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2 The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 4, 2023, subject to the reporting person's continued service with the Issuer.
F3 The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer.